ABSTRACT. The endogenously produced cytokine, tumor necrosis factor-a (TNF-a), has been shown in adult animal models to be associated with many of the pathophysiologic effects of sepsis, including systemic hypotension and hemorrhagic necrosis. TNF-a can induce the release of various vasoactive arachidonic acid metabolites, suggesting that TNF-a may act either directly or via intermediary substances in producing its effects. The pathophysiologic role of TNF-a in neonatal sepsis, especially its potential effect on pulmonary vascular tone, is presently unknown. To assess the role of TNF-a in neonatal sepsis, 19 piglets (19
PIM, pulmonary intravascular macrophage PG, prostaglandin
Experimental sepsis (1) or endotoxin (2, 3) administration increases both Ppa and PVR, Increased Ppa and PVR can promote or inhibit eficient VA/Q matching by altering Qp distribution. In neonatal animals, (GBS)-induced increase in PVR is associated with immediate and sustained hypoxemia (4, 5) . The arachidonate metabolite TxA2 is associated with an increase in PVR acutely after the onset of neonatal experimental GBS or other gram-positive sepsis (6, 7) . Use of the Tx synthase inhibitor dazmegrel blunts pulmonary hypertension occurring both with onset of GBS infusion (6) and when used after 2 h of infusion (8) , but fails to reverse the hypoxemia in the latter situation (8) . The role of other vasoactive agents in both the immediate and later phases of neonatal sepsis is unknown. The vasoactive cytokine, TNF-a, a 157 amino acid polypeptide synthesized and released by mononuclear phagocytes, induces many signs of sepsis in adult animals models (9) . In addition, TNF-a in vitro induces release of vasoactive arachidonate metabolites including TxB2 (10) . The adverse effects of TNF-a infusion have been prevented by pretreatment with the cyclooxygenase inhibitor indomethacin (1 1). Specific inhibitors of TxA2 formation have not been assessed during TNF-a induced disease.
We used the vigorous and reproducible pulmonary vasoconstrictive response found in the neonatal piglet (5, 12) to test the hypothesis that infusion of TNF-a would induce an increase in Ppa and PVR associated with a concomitant deterioration in pulmonary gas exchange. We further hypothesized that the pulmonary hemodynamic alteration induced by TNF-a would be prevented by pretreatment with the specific thromboxane synthase inhibitor, dazmegrel, (UK 38,485). pentobarbital and also received 200 U/kg of heparin. They were mechanically ventilated via a metal tracheostomy tube at a tidal volume of 12 + 2 mL/kg at a rate that maintained arterial Pco2 at approximately 40 + 5 torr (5.1 f 1 kPa). Animals were paralyzed with 0.3 mg/kg pancuronium bromide intravenously; anesthesia and paralysis were maintained for the duration of the experiment with administration of 5 mg/kg of pentobarbital and 0.3 mg/kg of pancuronium as needed. Body temperature was monitored with a rectal probe (Yellow Springs Instrument Co., Yellow Springs, OH) and maintained with a heat lamp at a temperature of 38.5 + 0.5"C.
MATERIALS AND METHODS

Animalpreparation
A no. 5 FR thermodilution balloon-tipped catheter was placed rTNF-(Y AND PULMONARY HYPERTENSION 467 in the pulmonary artery using fluoroscopic monitoring. This catheter was used to measure continuously Ppa and intermittently measure Pcw, Qp, and to withdraw samples for mixed venous blood gas tensions and pH. A catheter was placed in the ascending aorta via the internal carotid artery to measure continuously Psa and to obtain blood for arterial blood gas tensions and pH. A double lumen catheter was inserted into a peripheral vein for continuous drug infusion. Expiratory tidal volume and respiratory frequency were measured by placing a pneumotachograph (Fleisch 00) (DynaSciences, Blue Bell, PA) in the expired gas stream just distal to a one-way valve on the expiratory side of a ventilator circuit (13) . Paw was measured continuously at the proximal tracheostomy port. All vascular and airway pressures were measured with Statham P23Db transducers, averaged to obtain mean values, and continuously recorded (Hewlett Packard 7758B multichannel recorder, Waltham, MA). Phasic pressure recordings were used to monitor heart rate. Pressures were recorded only during expiration. Pulmonary blood flow was measured by thermodilution technique. Three measurements using an Edwards 9520A cardiac output computer (American Edwards Laboratory, Irvine, CA) under each experimental condition were obtained and averaged. If the values varied by more than lo%, additional measurements were obtained. Blood gas tensions, pH, and inspired gas partial pressures were determined using a Corning 168 pH blood gas analyzer (Corning Medical, Medfield, MA). Samples were measured within 3 min of collection. An index of pulmonary vascular resistance was calculated from the formula: PVR = Ppa -Pcw + by Qp. Animals were ventilated with room air during the experiment.
TNFpreparation. rTNF-a, derived from Escherichia coli, was kindly supplied as a gift from Knoll Pharmaceutical Co. (Whippany, NJ). The material was supplied as a lyophilized powder; each glass vial contained 0.98 mg rTNF-a. The vials were kept frozen (-70°C) until the day of each experiment. The material was reconstituted to 100 pg/mL with sterile water containing 0.5 g/100 mL human serum albumin. Only glass syringes were used for reconstitution and administration, as rTNF-a adheres less to glass than to plastic. kimulus amebocyte lysate assay (Pyrotell, Associates of Cape Cod, Inc., Woods Hole, MA) was performed on one vial to detect any endotoxin present with the rTNF-a. A concentration between 6 and 60 pg endotoxin/mg rTNF-a was detected. To eliminate the possibility that this amount of endotoxin infused with the rTNF-a affected Ppa and PVR, piglets of the same age as the study animals received a 30-min infusion of E. coli lipopolysaccharide 055:0B5 (Sigma Chemical Co., St. Louis, MO) in total dosages ranging between 30 and 500 pg. No change in Ppa, PVR, Qp, Psa, or arterial blood gas tensions was detected with these doses during the infusion period or for 2.0 h afterward. 38, 485) , kindly supplied as a gift from Pfizer Pharmaceuticals, (Groton, CT) was administered in an 8-10 mg/kg dose. The material was supplied as a powder, and was dissolved just before infusion in 1 . O mL of 0.1 N NaOH, to which was added 4.0 mL 0.9% saline. Dazmegrel was then infused i.v. over a period of 5 min.
Dazmegrel preparation. Dazmegrel (UK
Assessment of ventilation perfusion matching. The multiple inert gas elimination technique (14, 15) was used to assess intrapulmonary shunt and distribution of VA/Q ratios. The technique requires continuous intravenous infusion of six inert gases (sulfur hexaflouride, ethane, cyclopropane, halothane, diethyl ether, and acetone) dissolved in 0.9% saline with 5% dextrose (5 mL/kg/h). Simultaneous sampling of pulmonary arterial and systemic arterial blood (4 mL) and mixed expired gas (20 mL) was then performed. The expired gas sample was obtained in a heated syringe to avoid condensation of water vapor in the exvired gas and loss of soluble expired inert gases Intrapulmonary shunt, defined as percent perfusion to areas of zero ventilation, and a unitless index of ventilation-perfusion heterogeneity separate from shunt and dead space, the SD of perfusion (8, 16) , were used as indices of VA/Q matching. Special care was taken to maintain constant hematocrit and temperature during the experimental protocol to avoid fluctuations in the blood gas partition coefficient during the experiment (17) .
Measurement of plasma thromboxane BZ RIA was performed for measurement of TxB2, the stable breakdown product of TxA2, on arterial plasma samples obtained at baseline and at the end of the rTNF-a infusion. The details of the methodology used in our laboratory have been previously published (8) . In brief, at each sampling time, a 2-mL sample of arterial blood was obtained by drawing the blood through a short plastic catheter directly into previously prepared fresh, cold inhibitor solution containing indomethacin and sodium EDTA. Samples were kept in an ice bath until centrifugation (1 5 000 rpm X 15 min at 4.0°C). Plasma was decanted, frozen, and stored at -70°C. until RIA was performed. Samples were then analyzed in duplicate according to standard protocol (18, 19) . No matrix effects due to protein present in unknown piglet plasma samples were found when standard curves run with eicosanoid-free piglet plasma prepared by charcoal stripping were compared to curves generated from samples not treated with charcoal. The antibody against TxBz that was employed in the RIA was produced in our laboratory and had a sensitivity of 1 pglO.1 mL sample at a dilution of 1: 100 000 (19) . The cross-reactivities of this anti-TxBz antiserum have been published previously (8, 19) . Experimental protocol. After the instrumentation and preparation, baseline data were obtained to confirm that the animals met minimal criteria for further investigation. Criteria included absence of metabolic acidosis, (calculated base deficit 5 -9 mEq/ L) arterial pH 2 7.35, arterial Po2 r 70 torr (9 kPa) during room air ventilation, and systemic arterial blood pressure > 60 torr (8 kPa) . Three animals from an original group of 22 were rejected based on these criteria; the 19 remaining animals form the basis of this report. Once baseline data, including blood samples for respiratory and inert gas analysis and for TxB2 assay were collected, the animals were randomized to receive either dazmegrel (nine animals) or no pretreatment (10 animals). Infusion of the carrier substance for dazmegrel has been previously shown to have no cardiovascular effects on similar aged piglets (6) .
Twenty min after the dazmegrel administration to animals assigned to the dazmegrel group, a second set of samples was obtained. After this new baseline evaluation, animals in both groups received a continuous intravenous infusion of rTNF-a. A total of 0.98 mg rTNF-a was administered during the 30-min period. In the dazmegrel pretreated animals, if no change in pulmonary artery pressure was detected at the initial infusion dosage, the rTNF-a dose was briefly doubled to attempt to elicit any change in Ppa at the higher dose. No change in Ppa was noted.
Systemic and pulmonary arterial pressures were monitored continuously throughout the infusion. Hemodynamic measurements were monitored continuously and recorded 20 min after the initiation of the rTNF-a infusion. Blood for repeat TxB2 assay was obtained at the end of the rTNF-a infusion (30 min).
Statistical analysis. Analysis of variance was performed to determine if there were any significant changes in mean values for gas exchange or PVR at each experimental time point within each group. If so, a paired t test was used with correction for multiple comparisons (20) to determine if any of the experimental values differed from the baseline for each group of piglets. Between group comparisons were made with the unpaired t test.
Data are expressed as the mean and SD of each group of animals.
into the water ;apor.-samples were then analyzed using a gas chromatograph and an electron-capture detector to measure RESULTS relative concentration of each of the six inert gases in each Effect of rTNF-a on pulmonary hemodynamics. The rTNF-a sample. infusion produced an immediate rise in Ppa (Fig. 1) and PVR ( Fig. 2) in the nonpretreatment group. The increases were sus-until 2 h, by which time the mean PVR was equal between the tained throughout the remainder of the experimental time two groups. period, including up to 2 h after onset of infusion, compared to Qp, plotted against time of the experiment, is shown in Figure  baseline data. In contrast, when compared to baseline data, no 3. There was no significant decrease until 2 h, compared to significant effect in the dazmegrel-pretreated group was noted on baseline for each group. Baseline Qp did not differ between the Ppa until 1 h after onset of infusion, and on calculated PVR two groups. Effect ofrTNF-a on gas exchange. The elevation of Ppa and PVR was not associated with deterioration in pulmonary gas exchange as assessed by arterial Po2, by change in percent shunt or mismatching of ventilation perfusion as assessed by low VA/ Q area or SD or perfusion when these data were compared to baseline for each group (Table 1) . Arterial pH and P C O~ did not change during the period of time studied in each group. The mean arterial pH for each group ranged between 7.43 and 7.35 at the experimental times. Mean airway pressure also did not change with the rTNF-a infusion.
Effect of rTNF-a on systemic blood pressure. Mean Psa is shown for both groups (Table 2 ). Only at 2 h postinfusion was there a significant but still modest decline in mean systemic pressure in each of the groups of animals compared to baseline data. There was no change in mean heart rate during the experimental period in either group compared to baseline values.
Effect of rTNF-a on TxB2. Results of baseline and 30-min arterial plasma TxB2 levels are shown (Fig. 4) . Although there was a trend toward increased TxB2 at 30 rnin after initiation of the infusion of rTNF-a, the mean increase of 80% above baseline was not statistically significant because of the large variability of TxB2 values in the rTNF-a-treated group. There was no correlation between magnitude of increase in PVR and absolute or percent rise in TxB2 from baseline to 30 min in this group. No trend toward rising rTNF-a levels was detected in the dazmegrelpretreated animals between the baseline and 30-min measurement points (Fig. 4) . Mean values for baseline plasma TxB2 in the two groups were not significantly different.
DISCUSSION
Infusion of rTNF-a resulted in a 220% increase in PVR by 10 min and an approximately 100% increase for the remainder of the acute experimental period. These results may represent the minimal vasoactive effect of TNF-a. We have preliminary evidence that there is significant homology between porcine and human TNF-a (Gibson RL, unpublished observations). The dosage of rTNF-a used in the present experiment was based on pilot studies. Those studies demonstrated that a 3-fold higher infusion rate resulted in systemic hypotension and bradycardia. By contrast, pilot study dosage levels of 0.1 to 0.3 of the present dose produced no detectable change in Ppa, at least during a 30-min infusion. Dazmegrel, an advanced form imidazole inhibitor of the enzyme TxA2 synthase (21), blocks thromboxane A2 production without affecting the synthesis of intermediary products in the arachidonate metabolite pathway (2 1). The dosage of dazmegrel used in our study was similar to that used in previous studies examining neonatal group B streptococcal sepsis (6) and endotoxin-induced shock (22) , in which dazmegrel abrogated acute elevations in plasma TxB2 levels (6). Dosage of dazmegrel was similar to that used by others to achieve complete TxA2 synthase inhibition in vivo (22) . The use of TxB2 as an indicator of the synthesis of the vasoconstrictor TxA2 has been criticized because it is a nonenzymatic breakdown product and easily generated in vitro by sample handling (23) . However, the relatively low level of TxB2 found in our study during baseline conditions, compared to baseline measurements by others (24) is evidence against inadvertent conversion of TxA2 to TxB2 during specimen handling.
The lung of the neonatal piglet demonstrates several similarities to the lung of the newborn human. There is architectural similarity, characterized by common lack of collateral ventilation, and by common postnatal development of the pulmonary vasculature (12, 25) . Although both the human and porcine lung may contain PIM, which may participate in the pulmonary vasoconstrictive response (26) , including during bacterial infusion (27) , there are differences in the number of PIM between species (28). These differences in number of PIM, as well as agedependent pulmonary vascular muscular development, may both be determinants of the pulmonary vascular response to sepsis (29, 30) . Of interest is that in three pilot studies of rTNFa infusion in piglets 4-7 d old, a similar pulmonary hypertensive response to a similar dose/kg of rTNF-a was elicited. Our hemodynamic and gas exchange measurements are consistent with findings by others of similarities in piglet lung functional development between 1 and 2 wk of age (31) . The postnatal age of the animals in the present study eliminated contribution to Qp from a patent ductus arteriosus (32) .
TNF-cu induces many of the characteristics of septic shock, including systemic hypotension, disseminated intravascular coagulation, and multifocal hemorrhagic necrosis (9, 33) . TNF-a induces pulmonary edema in neutrophil sufficient guinea pigs after i.v. infusion (34) . However, effects of TNF-a on Ppa and PVR are not consistent between experiments. Guinea pigs that were infused with TNF-a showed modest and transient elevations in Ppa (34) . In contrast, adult sheep demonstrated a marked but also transient pulmonary hypertensive response of rapid onset (35) . Both findings are in contrast to our study, which demonstrated acute onset but sustained elevation in pulmonary vascular resistance up to 2 h after onset of the infusion. It may be that the more vigorous pulmonary vasoconstrictive response to other stimuli noted in neonates of other species (36) was relevant in this animal model.
The mechanism of action of the pulmonary vasoconstriction of rTNF-a is uncertain. Some of the acute actions of TNF-a are mediated via arachidonate metabolites in adult animal models (1 1). The same pathways may exist in neonatal animals. TNF-a causes an increase in TxB2 release when incubated with rat peritoneal macrophages and human peripheral blood neutrophils in cell culture (10) . TNF-a incubation with monocytes releases platelet-activating factor (37) . Some of the septic shock-like effects of TNF-a can be blocked in rats by pretreatment with a cyclooxygenase inhibitor (1 1). TNF-a is also capable of inducing synthesis of PGE2, a known pulmonary vasodilator (38) . In endothelial cell cultures, established with cells obtained from pulmonary artery and lung microvascular endothelial cells, TNFa induced release of both vasodilators PGE2 and PG12, with PGE2 predominating in the microvascular endothelial cell culture, suggesting a differential site-specific effect of TNF-a (39). The results of our study are not completely consistent with TNF-a inducing and sustaining pulmonary hypertension solely on the basis of TxA2 release. TNF release cannot explain all the pathophysiologic effects previously demonstrated in neonatal piglet models of GBS sepsis ( 5 , 6) . Thromboxane has been demonstrated to be a pulmonary venoconstrictor and an inducer of pulmonary edema (40) . Widespread alveolar pulmonary edema would be expected to interfere with gas exchange, which was not found in these studies. Therefore, it is possible that TNFcu fails to stimulate release of some vasoactive factors that may contribute to VJQ mismatching; or less likely, that some of the other vasoactive substances that may also be released by TNF-a induction may help preserve pulmonary gas exchange.
The suggestion that TNF-a may be a mediator of pulmonary hypertensive vascular disorders is strengthened by findings that neonatal monocytes are capable of synthesizing and releasing TNF-cu (4 I), and by the finding that alveolar monocytes produce a greater quantity of TNF-a than circulating peripheral blood monocytes (42) .
Our findings, and the demonstration that TNF-a is detectable in large quantities in the plasma of a neonatal animal model of GBS sepsis (43) , provide evidence that TNF-a may be an important mediator in pulmonary hypertensive conditions in the neonate.
